Histamine and Bradykinin Pharmacology

Histidine decarboxylase converts the amino acid histidine to histamine in a single irreversible step. Once synthesized, histamine is stored in secretory granules where it is bound ionically to heparin proteoglycans, allowing stable long-term storage and rapid release upon cell activation. Unlike the catecholamines, there is no reuptake transporter for histamine; after release it is inactivated extracellularly by two enzymatic pathways — histamine N-methyltransferase in most peripheral tissues and diamine oxidase in the gastrointestinal tract — and its plasma half-life after mast cell degranulation is measured in minutes.

Each of the four histamine-storing cell populations has a distinct anatomical location and a distinct physiological function. This distribution directly predicts which clinical syndromes arise from histamine release and which receptor subtypes are pharmacologically relevant in each context.

The canonical allergic pathway requires two exposures. On first exposure to an allergen, genetically susceptible individuals produce immunoglobulin E antibodies that bind to high-affinity immunoglobulin E receptors on mast cells and basophils, arming them. On re-exposure, the same allergen crosslinks adjacent receptor-bound immunoglobulin E molecules. This crosslinking triggers a signaling cascade that causes rapid granule-plasma membrane fusion and release of preformed histamine, tryptase, and heparin within seconds to minutes.

Because sensitization is required, true immunoglobulin E-mediated reactions cannot occur on first exposure to a drug or allergen. This is the basis of the clinical distinction between anaphylaxis (immunoglobulin E-mediated, requires prior sensitization) and anaphylactoid reactions (non-immunoglobulin E-mediated, can occur on first exposure). Both produce the same multisystem syndrome and are managed identically with epinephrine as first-line treatment.

Several drug classes directly activate mast cells without involving immunoglobulin E, producing histamine release on any exposure — including the first. This mechanism underlies a set of predictable, dose- or rate-dependent adverse drug reactions that are commonly encountered in clinical practice.

Complement activation also generates non-immunological histamine release. The complement fragments C3a and C5a (anaphylatoxins) bind receptors on mast cells and basophils to trigger degranulation. This occurs in transfusion reactions, drug-induced immune complex formation, and certain infections. The clinical syndrome it produces is managed identically to immunoglobulin E-mediated anaphylaxis.

The H1 receptor couples to the Gq protein, activating phospholipase C and raising intracellular calcium. It is expressed prominently on vascular endothelium, vascular and bronchial smooth muscle, sensory neurons (particularly the C fibers that mediate pruritus), and central nervous system neurons of the tuberomammillary nucleus. The physiological consequences of H1 activation differ by tissue: in vascular endothelium it triggers nitric oxide production, producing vasodilation and increased vascular permeability (the basis of wheal formation); in bronchial smooth muscle it causes contraction and bronchoconstriction; in sensory C fibers it produces the itch sensation; and in central nervous system neurons it promotes cortical arousal and wakefulness.

H1 antihistamines are technically inverse agonists rather than simple competitive antagonists — they preferentially stabilize the inactive receptor conformation, suppressing constitutive receptor activity. For clinical purposes the practical effect is the same as competitive antagonism: blockade of histamine-mediated allergic responses.

The H2 receptor couples to the Gs protein, activating adenylyl cyclase to raise cyclic adenosine monophosphate levels, which activates protein kinase A. In gastric parietal cells, protein kinase A activates the hydrogen-potassium ATPase (the proton pump), stimulating acid secretion. Enterochromaffin-like cells release histamine onto adjacent parietal cells in response to gastrin and acetylcholine, making histamine the final common amplifier of acid secretion by all three stimuli — the pharmacological rationale for H2 blocker therapy.

H2 receptors are also present on cardiac myocytes, where activation produces modest increases in heart rate and contractility via cyclic adenosine monophosphate. This contributes to the tachycardia seen in anaphylaxis alongside the dominant H1-mediated vasodilation.

H3 receptors are Gi-coupled presynaptic autoreceptors on histaminergic nerve terminals in the central nervous system. When activated by locally released histamine, they inhibit further histamine synthesis and release, forming a classic negative feedback loop. H3 receptor inverse agonists (pitolisant) disinhibit histaminergic neurons, promoting wakefulness — the basis of pitolisant's indication for narcolepsy. H3 pharmacology is low-yield for Step 1 outside of narcolepsy drug identification.

H4 receptors are Gi-coupled and expressed predominantly on immune cells including mast cells, basophils, and eosinophils, where they modulate immune cell chemotaxis and activation. No H4-selective drug has reached major clinical use at the Step 1 level.

Intradermal histamine release produces the triple response: a red spot at the site from local arteriolar vasodilation (H1 on vascular endothelium); a surrounding wheal from plasma extravasation through H1-mediated increased vascular permeability; and an irregular flare of erythema extending beyond the wheal, produced by an axon reflex that dilates surrounding arterioles. The itch accompanying this response is mediated by H1 receptor activation of sensory C fibers. The triple response is the skin correlate of urticaria and reproduces in miniature the local vascular events of acute allergy.

In systemic anaphylaxis, massive mast cell and basophil degranulation releases histamine alongside prostaglandins, leukotrienes, platelet-activating factor, and tryptase. Histamine is the primary mediator of the cutaneous manifestations (flushing, urticaria, angioedema) and contributes to cardiovascular collapse through H1-mediated vasodilation and increased vascular permeability. However, the multimediator nature of anaphylaxis is why antihistamines alone cannot reverse anaphylactic shock.

Epinephrine is the only agent that simultaneously addresses the multimediator, multisystem problem: it reverses vasodilation via alpha-1 adrenergic receptors, reverses bronchoconstriction via beta-2 adrenergic receptors, and supports cardiac output via beta-1 adrenergic receptors. H1 antihistamines reduce pruritus and urticaria as useful adjuncts but have no effect on hemodynamic collapse or bronchospasm and are never first-line treatment for anaphylaxis.

H1 receptor activation on bronchial smooth muscle produces bronchoconstriction, contributing to the early-phase bronchospasm in asthma after allergen exposure. This effect is significantly amplified in patients with asthma, whose airways are hyperresponsive to histamine. H1 antihistamines provide modest bronchodilatory benefit in allergic asthma but are not primary asthma therapy — the late-phase inflammatory response driven by leukotrienes and eosinophils is not histamine-mediated and is not addressed by antihistamines.

H2 receptor activation in the gastric mucosa drives acid secretion via the enterochromaffin-like cell to parietal cell paracrine pathway described in Section 3. This is the pharmacological basis of H2 blocker therapy for peptic ulcer disease and gastroesophageal reflux disease, covered in Module 3.